Merck and Mayo Clinic Partner for AI Drug Discovery

Merck and the Mayo Clinic have launched a strategic research agreement to advance drug discovery using artificial intelligence ^[1][2]. The collaboration focuses on applying AI and multimodal clinical data to better understand complex diseases ^[1]. The partnership aims to utilize virtual cell technologies to improve disease modeling ^[1]. Researchers will specifically target conditions like multiple sclerosis and inflammatory bowel disease ^[1][2]. By bridging clinical data with AI, the teams hope to identify new therapeutic targets more efficiently ^[2]. This alliance represents a significant step in integrating healthcare data with pharmaceutical research ^[2]. Separate from this deal, the Mayo Clinic recently installed specialized systems for cancer research, highlighting its broader technological expansion ^[3].